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Abstract
We report a retrospective study of 24 patients with haemato-
logical malignancy and hepatosplenic candidiasis. Clinical and
biological features were similar to previous reports. No
patient previously received antifungal prophylaxis. Liver or
spleen histological examination revealed yeasts in 6/24 patients
(25%) on direct examination but all cultures were negative.
After a median duration of 7 months, antifungal treatment was
discontinued in 58% of the patients with no relapse. Eleven
(46%) patients died during follow up. After multivariate analy-
sis, independent factors associated with death were the dura-
tion of neutropenia (p 0.022) and relapsing haematological
malignancy (p 0.015).
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Before the availability of the newer azoles or echinocandins
and the widespread use of systematic antifungal prophylaxis,
the incidence of hepatosplenic candidiasis (HSC) varied
between 2% and 9% in patients with acute leukaemia or after
allogeneic stem cell transplantation [1–5]. Deﬁning the most
accurate diagnostic criteria and treatment remains a chal-
lenge because HSC is a rare disease.
All cases of HSC diagnosed between 2000 and 2007 in
two major centres caring for patients with haematological
malignancies in Paris were retrospectively included in this
study. Cases were classiﬁed according to the deﬁnitions pro-
posed by the European Organization for Research and Treat-
ment of Cancer/Mycoses Study Group (EORTC/MSG) as
conﬁrmed, probable or possible cases, but 1,3-b-D-glucan
monitoring was not routinely performed in our centres [6].
We deﬁned response to treatment as resolution of all clini-
cal and biological signs with imaging studies showing stable
size or reduction of size or number of lesions, when nodules
resolved or calciﬁed on imaging procedures and if no relapse
occurred after antifungal treatment discontinuation. Failure
of therapy was deﬁned by persistence of clinical signs or
nodules worsening on imaging studies and also by death
within the ﬁrst 3 months of antifungal therapy or if relapse
occurred after antifungal treatment discontinuation. Survival
curves were estimated using a Kaplan–Meier estimator, and
association of patients’ characteristics with survival was anal-
ysed using a Cox proportional hazards models.
We report 24 cases of HSC occurring during a 7-year per-
iod: 6 were proven HSC, 3 were probable HSC and 15 were
possible HSC. The characteristics of the patients are given in
Table 1. Only 25% were proven HSC, which appears to be
lower than in previous studies [7,8]. Our deﬁnition of cases
was retrospectively based on 2008-revised EORTC/MSG
study group diagnostic criteria for invasive mycoses, which
were different from previous studies that only collected pro-
ven HSC [8]. For 62% of our cases, the diagnosis relied only
on imaging procedures showing hepatic or splenic nodules in
haematological patients. The culture of liver biopsy was nega-
tive in all 13 patients (54%) who underwent liver biopsy and
direct examination showed budding yeasts or pseudohyphae
consistent with Candida infection in only four of the 13 patients
(31%). The same histological ﬁndings were found on two
spleen specimens (one splenectomy and one autopsy). The
detection of mannan antigenaemia and anti-mannan antibodies,
b-D-glucan or PCR could have been useful indirect markers for
an earlier diagnosis of HSC and to monitor response to treat-
ment as suggested in some studies, but they were not available
in our centres at the time of the study [9].
The most unusual ﬁnding when comparing our series with
previous clinical studies was that up to 40% of the patients
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had concomitant pulmonary involvement, a ﬁnding which has
also been found in other reports [10,11]. Candida coloniza-
tion was also very common, found in 92% of the patients,
and may have helped clinicians to adapt antifungal therapy.
None of the patients had previously received antifungal
prophylaxis but according to current guidelines the majority
of our patients would have been prescribed prophylaxis
today, thereby reducing the incidence of HSC [12,13]. Azoles
were the preferred regimens with ﬂuconazole or voriconaz-
ole used in 38% and 17% of the patients, respectively, fol-
lowed by caspofungin in 17% of the patients. The optimal
treatment is not yet deﬁned because few data are available
on the efﬁcacy of echinocandins or the newer azoles (vorico-
nazole, posaconazole) in the ﬁrst-line treatment of HSC, and
the recommended duration of therapy is usually 3–6 months
[14].
Deﬁning response to treatment in our patients was the
major pitfall. During the evolution of HSC, clinical signs, par-
ticularly fever, can persist for several weeks and are not usu-
ally considered as failure of therapy [15,16]. Steroids are
often prescribed (for 58% of our patients) because the
mechanism is believed to be immune restoration after recov-
ery of neutropenia [17,18]. As for other infectious diseases,
18-F-ﬂuoro-D-deoxyglucose positron emission tomography
(FDG-PET) could be promising for the evaluation of
response to therapy [19]. This technique was not routinely
performed during our study period except for a few patients,
so we were not able to deﬁne response to treatment based
on FDG-PET results and further studies are mandatory.
If we consider as proposed by EORTC/MSG study group
that death from any cause should be considered as failure of
therapy, response to therapy would be 54% in our study
whereas if we exclude patients who died during follow-up
from any other cause, as proposed by other authors, only
two patients (17%) could be considered as failures (the
patient whose diagnosis was conﬁrmed by autopsy and the
patient with persistent yeasts on liver biopsy) and response
to therapy would be 82%. The most accurate criteria for
cure in our study may be the absence of relapse of HSC
after antifungal treatment was discontinued, which was the
case for 58% of the patients.
Analysing predictors of response to therapy was not feasi-
ble and we chose instead to evaluate mortality risk factors.
As the choice of treatment may have been biased by many
factors (such as disease severity), we chose not to include
the type of treatment as a variable in our model. We found
that a duration of neutropenia >1 month and haematological
relapse were both strongly predictive of death (Table 2). In
our study, for 79% of the patients, the intensive chemother-
apy programme was either interrupted or delayed, which
may have contributed to the high relapse rates and explain
why, for all the patients who died, the malignancy was not
controlled. Also, in the Kaplan–Meier model, the 2-year sur-
vival was estimated to be 50% in our study, which did not
seem to be lower than what is usually expected in patients
TABLE 1. Description of the 24 cases of hepatosplenic can-
didiasis
No. patients 24 n, %
Male gender, n (%) 13 (54)
Age at HSC diagnosis (years), median (range) 46 (2–76)
Duration of follow-up after HSC diagnosis (months),
median (range)
25 (0–62)
Haematological malignancy, n (%)
Acute leukaemia (ALL or AML) 18 (75)
Lymphoma 4 (17)
Autologous stem cell transplantation (testicular carcinoma) 1 (4)
Chronic neutropeniaa 1 (4)
Clinical signs, n (%)
Fever 23 (96)
Hepatomegaly 19 (79)
Splenomegaly 13 (54)
Right upper quadrant abdominal pain 9 (37)
Respiratory signs (cough, dyspnoea) 11 (46)
HSC localization, n (%)
Liver + spleen 16 (67)
Spleen 3 (13)
Liver 5 (21)
Kidney 3 (13)
Lungs 10 (42)
Histology results, n (%) 14 (58)
Positive direct examination 6 (25)
Positive culture 0 (0)
Granuloma 5 (21)
Hepatic tests
Elevated transaminases 7 (29)
Elevated alkaline phosphatase 21 (87)
Elevated c-glutamyl transferase 22 (92)
Candidaemia 3 (12.5)
First-line antifungal therapy for HSC (n = 24)a
None, n (%)b 1 (4)
Azoles, n (%) 13 (54)
Polyenes, n (%) 3 (13)
Caspofungin, n (%) 4 (17)
Combination, n (%)** 3 (13)
Maintenance antifungal therapy for HSC (n = 24)a
None, n (%)b 1 (4)
Azoles, n (%) 15 (62)
Polyenes, n (%) 3 (13)
Caspofungin, n (%) 3 (12)
Others, n (%)*** 2 (8)
Total duration of curative antifungal therapy (months),
median (range) (n = 23)b
7 (2–25)
Steroid therapy for HSC, n (%)c 14 (58)
Treatment failure, n (%) 5 (21)
No response to antifungal therapyd 1 (4)
Death <3 months after HSC diagnosis 4 (17)
HSC, hepatosplenic candidiasis; ALL, acute lymphoblastic leukaemia; AML, acute
myeloid leukaemia.
aFirst-line antifungal treatment was deﬁned as the treatment initiated after HSC
diagnosis and administered for at least 7 days within the ﬁrst 2 weeks of treat-
ment; maintenance treatment was deﬁned as the treatment the patient was
receiving 3 months after the diagnosis of HSC.
bOne patient with chronic neutropenia died before HSC or haematological
diagnosis was achieved and before receiving curative treatment. Autopsy dem-
onstrated HSC and Candida pneumonia in this patient.
cMean dosage of 1 mg/kg/day with a median duration of 1.5 months (range 1–
10).
dThis patient was followed-up 18 months after diagnosis of HSC, with uncon-
trolled malignancy. She did not respond to several lines of antifungal therapy
and did not receive steroids; liver biopsies performed during follow-up revealed
Candida pseudo-hyphae on smear examination.
**AmphoB deoxycholate + itraconazole(n = 1), caspofungin + voriconazole
(n = 2).
***Caspofungin + voriconazole (n = 1), itraconazole (n = 1).
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with acute leukaemia who achieve complete remission after
induction chemotherapy [20].
In conclusion, deﬁning the best antifungal treatment as
well as response to therapy remains uncertain. However, a
simple criterion to deﬁne cure could be the absence of
relapse of HSC after discontinuation of antifungal treatment.
Azoles are highly effective and are a good option to pro-
longed oral treatment. The association of non-invasive diag-
nostic procedures now needs prospective evaluation.
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TABLE 2. Univariate and multivariate models for survival analysis
Variable
Univariable model Multivariable model
HR (95% CI) p HR (95% CI) p
Female gender 2.52 (0.72–8.85) 0.15 – –
Age (per 10 years) 1.29 (0.96–1.73) 0.091 – –
>45 year 1.57 (0.46–5.39) 0.47 – –
No haematological remission at HSC 5.12 (1.34–19.6) 0.017 5.60 (1.39–22.5) 0.015
Duration of neutropenia (per week) 1.46 (1.08–1.96) 0.013 – –
>1 month 3.96 (1.20–13.1) 0.024 4.33 (1.24–15.2) 0.022
Candida colonization 0.50 (0.11–2.39) 0.39 – –
Time to empiric therapy (per week) 0.40 (0.13–1.28) 0.12 – –
Steroid therapy for HSC 0.61 (0.19–2.00) 0.41 – –
Delayed chemotherapy because of HSC 1.16 (0.24–5.52) 0.85 – –
HSC, hepatosplenic candidiasis; HR, hazard ratio; 95% CI, 95% conﬁdence interval.
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